Welcome to our dedicated page for Arrowhead Pharma SEC filings (Ticker: ARWR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Arrowhead Pharmaceuticals filings document regulatory disclosures for a commercial-stage RNAi therapeutics company with common stock registered on the Nasdaq Global Select Market. Form 8-K reports furnish fiscal results, Regulation FD clinical-data presentations, material agreements and capital-structure updates, including disclosures tied to convertible senior notes.
Proxy and annual-meeting filings cover board elections, executive-compensation votes, incentive-plan approvals and auditor ratification. The filing record also documents securityholder voting outcomes, governance matters, and disclosures related to programs such as REDEMPLO, ARO-INHBE and ARO-ALK7, alongside the company’s RNAi platform, development pipeline and commercial activities.
ARWR submitted an amended Form 144/A reporting a proposed resale of 100,000 common shares by Daniel Apel. The filing lists the shares as issued for compensation (a bonus) with an original grant date of 04/15/2025 and the Form 144/A date of 04/22/2026.
ARWR insider notice: Hongbo Lu filed a Form 144/A disclosing proposed sale of 2,970 shares of common stock, with an aggregate amount shown as $228,298.95. The filing lists 03/15/2026 and an execution/filing date of 05/12/2026, and identifies the sale reason as compensation.
James Hamilton reported proposed sales of Common Stock via a Form 144/A. The filing lists a proposed sale of 10,000 shares. The filing also records past transactions: a sale of 10,000 shares on 03/05/2026 for $641,870.05, and multiple compensation issuances on 01/04/2026 totaling 10,000 shares across four line items (5,708; 542; 1,628; 2,122).
Arrowhead Pharmaceuticals director Hongbo Lu reported an open-market sale of company stock. On the reported date, Lu sold 2,970 shares of Arrowhead Pharmaceuticals common stock at a price of $76.88 per share in a single transaction.
The filing states this sale was made under a pre-arranged Rule 10b5-1 trading plan, which is designed to allow insiders to sell shares on a scheduled basis. After this transaction, Lu directly owned 52,012 shares of Arrowhead Pharmaceuticals common stock, which includes shares underlying previously granted restricted stock units, some of which are still subject to vesting conditions.
Arrowhead Pharmaceuticals, Inc. reported a sharp swing to a loss for the quarter ended March 31, 2026. Revenue was $73.7 million, down from $542.7 million a year earlier, when it booked large milestone payments, leading to a net loss attributable to Arrowhead of $132.7 million versus net income of $370.4 million in the prior-year quarter.
For the first six months, revenue totaled $337.8 million and the net loss was $101.9 million. Cash, cash equivalents and restricted cash were $188.5 million, with available-for-sale securities of $1.60 billion, supporting ongoing R&D spending of $350.5 million over six months and a growing collaboration portfolio with Sarepta, Novartis and Sanofi.
Arrowhead Pharmaceuticals reported fiscal 2026 second quarter revenue of $73.7 million, down sharply from $542.7 million a year earlier, leading to a net loss of $132.7 million or -$0.93 per diluted share versus net income of $370.4 million or $2.75 previously. Total cash resources rose to $1.78 billion as of March 31, 2026, supported by concurrent offerings of $700 million in 0.00% convertible senior notes due 2032 and a $230 million common equity issuance, plus a capped call to limit dilution.
The company highlighted growing commercial traction for REDEMPLO in familial chylomicronemia syndrome, with more than 400 prescriptions, about 180 patients shipped, and most use in patients new to the APOC3 class. Arrowhead also expanded REDEMPLO’s global regulatory footprint, advanced its RNAi pipeline in cardiometabolic disease and obesity, and signed a worldwide license with Madrigal Pharmaceuticals for ARO-PNPLA3, including a $25 million upfront payment and up to $975 million in potential milestones.
Arrowhead Pharmaceuticals filed a Schedule 13G reporting that FMR LLC beneficially owned 7,349,106.75 shares of common stock, representing 5.2% of the class as shown in the filing. The cover shows sole voting power of 7,323,647.12 and sole dispositive power of 7,349,106.75. The filing lists an Exhibit referencing a related 13d-1(k)(1) agreement.
Arrowhead Pharmaceuticals disclosure: Vanguard Capital Management reports beneficial ownership of 7,081,293 shares of Common Stock, representing 5.05% of the class. The filer reports sole voting power for 1,048,877 shares and sole dispositive power for 7,081,293 shares. The filing is signed on 04/29/2026.
Arrowhead Pharmaceuticals Inc ownership disclosure: Vanguard Portfolio Management reports beneficial ownership of 7,269,957 shares of common stock, representing 5.19% of the class. The filing states Vanguard has sole dispositive power over these shares and sole voting power over 123,821 shares. The holdings include securities held for Vanguard funds and managed accounts.